Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/14827
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.otherUniversidad San Pablo-CEU. Departamento de Ciencias Farmacéuticas y de la Salud-
dc.creatorMuñoz Aceituno, Ester-
dc.creatorButrón Bris, B.-
dc.creatorOvejero Benito, María del Carmen-
dc.creatorSahuquillo Torralba, Antonio-
dc.creatorBaniandrés Rodríguez, O.-
dc.creatorHerrera Acosta, E.-
dc.creatorRivera Diaz, R.-
dc.creatorFerran, M.-
dc.creatorSánchez Carazo, José Luis-
dc.creatorRiera Monroig, J.-
dc.creatorPujol Montcusí, J.-
dc.creatorVidal, D.-
dc.creatorCueva, P. de la-
dc.creatorGarcía Bustinduy, M.-
dc.creatorRuiz Villaverde, R.-
dc.creatorBallescà, F.-
dc.creatorLlamas Velasco, Mar-
dc.creatorNavares, Marcos-
dc.creatorPalomar Moreno, I.-
dc.creatorSánchez García, Irene-
dc.creatorGarcía Martínez, Jorge-
dc.creatorNovalbos, J.-
dc.creatorZubiaur, Pablo-
dc.creatorAbad Santos, Francisco-
dc.creatorDaudén, Esteban-
dc.creatorFuente, H. de la-
dc.date2023-
dc.date.accessioned2024-01-12T11:56:18Z-
dc.date.available2024-01-12T11:56:18Z-
dc.date.issued2023-Diciembre-28-
dc.identifier.citationMuñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, Sahuquillo-Torralba A, Baniandrés Rodríguez O, Herrera-Acosta E, Rivera-Diaz R, Ferran M, Sánchez-Carazo JL, Riera-Monroig J, Pujol-Montcusí J, Vidal D, de la Cueva P, García-Bustinduy M, Ruiz-Villaverde R, Ballescà F, Llamas-Velasco M, Navares M, Palomar-Moreno I, Sánchez-García I, García-Martínez J, Novalbos J, Zubiaur P, Abad-Santos F, Daudén-Tello E, de la Fuente H. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice. J Eur Acad Dermatol Venereol. 2023 Dec 28. doi: 10.1111/jdv.19782-
dc.identifier.issn1468-3083-
dc.identifier.urihttp://hdl.handle.net/10637/14827-
dc.description.abstractBackground: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation. Objective: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting. Methods: We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed. Results: A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR-146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83-0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes. Conclusion: We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non-response to this drug in patients with plaque psoriasis.en_EN
dc.language.isoenen_EN
dc.publisherWiley-
dc.relation.ispartofJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.es-
dc.rightsopenAccess-
dc.subjectPharmacogeneticen_EN
dc.subjectPsoriasisen_EN
dc.titlePharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practiceen_EN
dc.typeArtículo-
dc.identifier.doi10.1111/jdv.19782-
dc.relation.projectIDInstituto de Salud Carlos III, Grant/Award Number: PI01583-
dc.relation.projectIDFondo Europeo de Desarrollo Regional; Novartis-
dc.centroUniversidad San Pablo-CEU-
Aparece en las colecciones: Facultad de Farmacia




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.